2021
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update
Witkowski P, Philipson L, Kaufman D, Ratner L, Abouljoud M, Bellin M, Buse J, Kandeel F, Stock P, Mulligan D, Markmann J, Kozlowski T, Andreoni K, Alejandro R, Baidal D, Hardy M, Wickrema A, Mirmira R, Fung J, Becker Y, Josephson M, Bachul P, Pyda J, Charlton M, Millis J, Gaglia J, Stratta R, Fridell J, Niederhaus S, Forbes R, Jayant K, Robertson R, Odorico J, Levy M, Harland R, Abrams P, Olaitan O, Kandaswamy R, Wellen J, Japour A, Desai C, Naziruddin B, Balamurugan A, Barth R, Ricordi C, Collaborative T. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. American Journal Of Transplantation 2021, 21: 1365-1375. PMID: 33251712, PMCID: PMC8016716, DOI: 10.1111/ajt.16397.Peer-Reviewed Original ResearchConceptsRegulatory frameworkUnited StatesIslet allotransplantationStandard-of-care procedureUS clinical practiceClinical practiceType 1 diabetes mellitusRegulatory distinctionsMinimally manipulated tissuesInvestigation proceduresRegulatory updatesClinical trialsBiological drugsDecades of progressPatientsAllotransplantationIslet transplantationTransplantationIsletsHuman isletsRegulationDrugHuman cellsImminent demiseState
2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk